|Positive IHC detected in||human liver tissue, human ovary tumor tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Immunohistochemistry (IHC)||IHC : 1:100-1:400|
|Sample-dependent, check data in validation data gallery|
12036-1-AP targets CHI3L1/YKL40 in WB, IHC, IF,ELISA applications and shows reactivity with human, mouse samples.
|Tested Reactivity||human, mouse|
|Cited Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||CHI3L1/YKL40 fusion protein Ag2710|
|Full Name||chitinase 3-like 1 (cartilage glycoprotein-39)|
|Calculated molecular weight||383 aa, 43 kDa|
|GenBank accession number||BC008568|
|Gene ID (NCBI)||1116|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Chitinase 3-like-1 (CHI3L1/YKL-40/CGP-39/GP-39/hCGP-39) is a protein secreted from restricted cell types including colonic epithelial cells (CECs) and macrophages. CHI3L1 is an inflammation-associated molecule, and its expression is enhanced in persons with colitis and colon cancer. CHI3L1 is a 40 kDa protein and is produced by restricted cell types, including colonic epithelial cells (CECs) and macrophages. CHI3L1 can be detected in the Golgi apparatus and the endoplasmic reticulum, but its major sites of action seems to be extracellular as a secreted protein. (PMID:21763261)
Cancer Manag Res
LINC00963 Promotes Ovarian Cancer Proliferation, Migration and EMT via the miR-378g /CHI3L1 Axis.
Biochem Biophys Res Commun
Effects of chitinase-3-like protein 1 on brain death-induced hepatocyte apoptosis via PAR2-JNK-caspase-3.
BYSL Promotes Glioblastoma Cell Migration, Invasion, and Mesenchymal Transition Through the GSK-3β/β-Catenin Signaling Pathway.
SSEA-4 and YKL-40 positive progenitor subtypes in the subventricular zone of developing human neocortex.
MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases.
Chitinase 3-like-1 contributes to acetaminophen-induced liver injury by promoting hepatic platelet recruitment.